Imagine fixing a wobbly table leg by putting a small, custom-fit wedge inside the joint instead of bolting huge metal plates and screws around it. This technology does that for the human spine, locking the joints from the inside. It means surgeons only need a tiny skin nick instead of a major open surgery.
Current spinal fusion relies on invasive 'screw-bridges' that are complex to place and can cause severe complications, leading to painful revision surgeries and high healthcare costs.
A small 3D-printed implant (zLOCK) and a specialized instrument set designed to lock the facet joint from within via a percutaneous approach.
If you are an implant manufacturer dealing with the stagnation of 30-year-old pedicle screw technology — this project developed the zLOCK implant that eliminates the need for screws and rods. This allows for a percutaneous approach and potentially outpatient procedures.
If you are a clinic owner dealing with high costs and patient distress from invasive spinal surgeries — this project developed a system that locks the facet joint from within. This reduces the risk of misplaced screws and simplifies the surgical procedure.
If you are an insurer dealing with the tremendous economic cost of spinal revision surgeries — this project developed a minimally invasive fusion system. By reducing complications and enabling outpatient care, it lowers the overall cost of spinal instability treatment.
Based on available project data, specific pricing or cost-per-unit information is not provided.
The project utilizes 3D printing for the implants, which is a scalable manufacturing method, though specific production volumes are not listed.
Based on available project data, the technology is developed by ZygoFix Ltd, but specific patent numbers or licensing terms are not detailed.
The project aimed to achieve the CE-mark and has conducted pivotal clinical trials in Italy and Germany to validate the system.
The project period ran from 2022-04-01 to 2025-03-31, focusing on accelerating the time-to-market through validation and upgrades.
The project is led by a single SME, ZygoFix Ltd from Israel, representing a 100% industry ratio. This lean structure suggests a fast-track approach to commercialization, focusing directly on clinical validation and product refinement without the overhead of academic partners.
Contact ZygoFix Ltd in Israel
Contact us to explore licensing or partnership opportunities with ZygoFix.
